INS and type 1 diabetes mellitus: A recent clinical trial demonstrated that ex vivo expansion and subsequent infusion of autologous human Treg cells in 12 patients with newly diagnosed T1D lowered the patients’ exogenous insulin requirements and prolonged endogenous islet survival (194).